Description SUPPORTS YOUR GLP-1 JOURNEY If you're taking a GLP-1 medication, you know it can come with like low energy and digestive discomfort
Strengths of the present meta-analysis are the inclusion of all CVOTs published by 10 December 2021, the very large number of participants, the high quality of the trials which minimizes the risk of bias, and the absence of significant heterogeneity in most analyses, which ranged from absent to low or moderate
Data on atrial fibrillation outcomes with GLP-1 therapy usually come from secondary analyses rather than dedicated rhythm trials, which limits definitive conclusions
As such, Shirani continued, prescribing drugs such as metformin or pioglutazone may reduce disease activity revealed through MRI and may influence pro-inflammatory T-cell response
Conclusions Future studies will provide further insights to refine the role of these new drugs, continuing to expand their utility beyond T2D, to treat renalcardiometabolic conditions in a more integrated approach as a single entity to target
